Speech dysfunction in early Parkinson's disease.
Identifieur interne : 004A44 ( Ncbi/Merge ); précédent : 004A43; suivant : 004A45Speech dysfunction in early Parkinson's disease.
Auteurs : C. Stewart [États-Unis] ; L. Winfield ; A. Hunt ; S B Bressman ; S. Fahn ; A. Blitzer ; M F BrinSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1995.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Articulation Disorders (complications), Dysarthria (complications), Dysarthria (diagnosis), Humans, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Selegiline (administration & dosage), Selegiline (therapeutic use), Severity of Illness Index, Voice Disorders (complications).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Selegiline.
- chemical , therapeutic use : Antiparkinson Agents, Selegiline.
- complications : Articulation Disorders, Dysarthria, Parkinson Disease, Voice Disorders.
- diagnosis : Dysarthria.
- drug therapy : Parkinson Disease.
- Adult, Aged, Humans, Middle Aged, Severity of Illness Index.
Abstract
The purpose of this study is to determine if subjects in the early stages of untreated Parkinson's disease (PD) or PD treated with deprenyl alone suffer from motor speech abnormalities. Speech defects are common in advanced PD, including disturbances of respiration, phonation, and articulation. We studied 12 subjects with early PD (Hoehn and Yahr stage < or = 2, mean duration disease 3.2 years) who were not taking symptomatic therapy and tested them under two conditions: on and off deprenyl. None of the subjects was depressed or demented (Mini Mental Status mean 29.9/30; Hamilton Depression Rating mean 2.7/52). All functioned independently (Schwab and England Activities of Daily Living mean 93.1/100). Acoustic and speech productions were assessed using the DSP Sona-Graph 5500 and an evaluation of dysarthria. All 12 had at least two characteristics of dysarthria on examination, although 8 were not aware of it. Vocal tremor was identified on narrow band spectrogram for four subjects. Deprenyl did not have a consistent effect on speech. Ten subjects had no detectable change in speech on deprenyl, one was worse, and one was improved.
DOI: 10.1002/mds.870100506
PubMed: 8552106
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004939
- to stream PubMed, to step Curation: 004939
- to stream PubMed, to step Checkpoint: 004922
Links to Exploration step
pubmed:8552106Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Speech dysfunction in early Parkinson's disease.</title><author><name sortKey="Stewart, C" sort="Stewart, C" uniqKey="Stewart C" first="C" last="Stewart">C. Stewart</name><affiliation wicri:level="1"><nlm:affiliation>Department of Speech-Language Pathology and Audiology, New York University 10003-6674, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Speech-Language Pathology and Audiology, New York University 10003-6674</wicri:regionArea><wicri:noRegion>New York University 10003-6674</wicri:noRegion></affiliation></author><author><name sortKey="Winfield, L" sort="Winfield, L" uniqKey="Winfield L" first="L" last="Winfield">L. Winfield</name></author><author><name sortKey="Hunt, A" sort="Hunt, A" uniqKey="Hunt A" first="A" last="Hunt">A. Hunt</name></author><author><name sortKey="Bressman, S B" sort="Bressman, S B" uniqKey="Bressman S" first="S B" last="Bressman">S B Bressman</name></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author><author><name sortKey="Blitzer, A" sort="Blitzer, A" uniqKey="Blitzer A" first="A" last="Blitzer">A. Blitzer</name></author><author><name sortKey="Brin, M F" sort="Brin, M F" uniqKey="Brin M" first="M F" last="Brin">M F Brin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:8552106</idno><idno type="pmid">8552106</idno><idno type="doi">10.1002/mds.870100506</idno><idno type="wicri:Area/PubMed/Corpus">004939</idno><idno type="wicri:Area/PubMed/Curation">004939</idno><idno type="wicri:Area/PubMed/Checkpoint">004922</idno><idno type="wicri:Area/Ncbi/Merge">004A44</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Speech dysfunction in early Parkinson's disease.</title><author><name sortKey="Stewart, C" sort="Stewart, C" uniqKey="Stewart C" first="C" last="Stewart">C. Stewart</name><affiliation wicri:level="1"><nlm:affiliation>Department of Speech-Language Pathology and Audiology, New York University 10003-6674, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Speech-Language Pathology and Audiology, New York University 10003-6674</wicri:regionArea><wicri:noRegion>New York University 10003-6674</wicri:noRegion></affiliation></author><author><name sortKey="Winfield, L" sort="Winfield, L" uniqKey="Winfield L" first="L" last="Winfield">L. Winfield</name></author><author><name sortKey="Hunt, A" sort="Hunt, A" uniqKey="Hunt A" first="A" last="Hunt">A. Hunt</name></author><author><name sortKey="Bressman, S B" sort="Bressman, S B" uniqKey="Bressman S" first="S B" last="Bressman">S B Bressman</name></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author><author><name sortKey="Blitzer, A" sort="Blitzer, A" uniqKey="Blitzer A" first="A" last="Blitzer">A. Blitzer</name></author><author><name sortKey="Brin, M F" sort="Brin, M F" uniqKey="Brin M" first="M F" last="Brin">M F Brin</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Articulation Disorders (complications)</term><term>Dysarthria (complications)</term><term>Dysarthria (diagnosis)</term><term>Humans</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Selegiline (administration & dosage)</term><term>Selegiline (therapeutic use)</term><term>Severity of Illness Index</term><term>Voice Disorders (complications)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Articulation Disorders</term><term>Dysarthria</term><term>Parkinson Disease</term><term>Voice Disorders</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dysarthria</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Humans</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of this study is to determine if subjects in the early stages of untreated Parkinson's disease (PD) or PD treated with deprenyl alone suffer from motor speech abnormalities. Speech defects are common in advanced PD, including disturbances of respiration, phonation, and articulation. We studied 12 subjects with early PD (Hoehn and Yahr stage < or = 2, mean duration disease 3.2 years) who were not taking symptomatic therapy and tested them under two conditions: on and off deprenyl. None of the subjects was depressed or demented (Mini Mental Status mean 29.9/30; Hamilton Depression Rating mean 2.7/52). All functioned independently (Schwab and England Activities of Daily Living mean 93.1/100). Acoustic and speech productions were assessed using the DSP Sona-Graph 5500 and an evaluation of dysarthria. All 12 had at least two characteristics of dysarthria on examination, although 8 were not aware of it. Vocal tremor was identified on narrow band spectrogram for four subjects. Deprenyl did not have a consistent effect on speech. Ten subjects had no detectable change in speech on deprenyl, one was worse, and one was improved.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8552106</PMID><DateCreated><Year>1996</Year><Month>02</Month><Day>20</Day></DateCreated><DateCompleted><Year>1996</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>1995</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Speech dysfunction in early Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>562-5</MedlinePgn></Pagination><Abstract><AbstractText>The purpose of this study is to determine if subjects in the early stages of untreated Parkinson's disease (PD) or PD treated with deprenyl alone suffer from motor speech abnormalities. Speech defects are common in advanced PD, including disturbances of respiration, phonation, and articulation. We studied 12 subjects with early PD (Hoehn and Yahr stage < or = 2, mean duration disease 3.2 years) who were not taking symptomatic therapy and tested them under two conditions: on and off deprenyl. None of the subjects was depressed or demented (Mini Mental Status mean 29.9/30; Hamilton Depression Rating mean 2.7/52). All functioned independently (Schwab and England Activities of Daily Living mean 93.1/100). Acoustic and speech productions were assessed using the DSP Sona-Graph 5500 and an evaluation of dysarthria. All 12 had at least two characteristics of dysarthria on examination, although 8 were not aware of it. Vocal tremor was identified on narrow band spectrogram for four subjects. Deprenyl did not have a consistent effect on speech. Ten subjects had no detectable change in speech on deprenyl, one was worse, and one was improved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Speech-Language Pathology and Audiology, New York University 10003-6674, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winfield</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bressman</LastName><ForeName>S B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Fahn</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Blitzer</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brin</LastName><ForeName>M F</ForeName><Initials>MF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DC01139</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS24778</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>14611-51-9</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001184">Articulation Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004401">Dysarthria</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014832">Voice Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8552106</ArticleId><ArticleId IdType="doi">10.1002/mds.870100506</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Blitzer, A" sort="Blitzer, A" uniqKey="Blitzer A" first="A" last="Blitzer">A. Blitzer</name><name sortKey="Bressman, S B" sort="Bressman, S B" uniqKey="Bressman S" first="S B" last="Bressman">S B Bressman</name><name sortKey="Brin, M F" sort="Brin, M F" uniqKey="Brin M" first="M F" last="Brin">M F Brin</name><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name><name sortKey="Hunt, A" sort="Hunt, A" uniqKey="Hunt A" first="A" last="Hunt">A. Hunt</name><name sortKey="Winfield, L" sort="Winfield, L" uniqKey="Winfield L" first="L" last="Winfield">L. Winfield</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Stewart, C" sort="Stewart, C" uniqKey="Stewart C" first="C" last="Stewart">C. Stewart</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004A44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:8552106
|texte= Speech dysfunction in early Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:8552106" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |